Albumin-bound nanoparticles for targeted therapy

Yu Seok Youn

doi:10.1007/978-981-10-4361-1_136

Albumin-bound nanoparticles for targeted therapy

Yu Seok Youn

Department of Pharmacy

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

1 Scopus citations

Abstract

In this study, albumin nanoparticle formulations including a series of potential drugs for treating cancers, rheumatoid arthritis or pulmonary fibrosis, such as, paclitaxel, doxorubicin, TRAIL (TNF-related apoptosis inducing ligand) or tacrolimus, were developed by using nanoparticle albumin bound (Nab™) technology. Marked targetability and in vivo efficacies of these albumin nanoparticles were demonstrated in mouse disease models.

Original language	English
Title of host publication	6th International Conference on the Development of Biomedical Engineering in Vietnam, BME6
Editors	Toi Vo Van, Thanh An Nguyen Le, Thang Nguyen Duc
Publisher	Springer Verlag
Pages	801-803
Number of pages	3
ISBN (Print)	9789811043604
DOIs	https://doi.org/10.1007/978-981-10-4361-1_136
State	Published - 2018
Event	6th International Conference on the Development of Biomedical Engineering in Vietnam, BME 2016 - Ho Chi Minh, Viet Nam Duration: 27 Jun 2016 → 29 Jun 2016

Publication series

Name	IFMBE Proceedings
Volume	63
ISSN (Print)	1680-0737

Conference

Conference	6th International Conference on the Development of Biomedical Engineering in Vietnam, BME 2016
Country/Territory	Viet Nam
City	Ho Chi Minh
Period	27/06/16 → 29/06/16

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Albumin
Albumin-bound technology
Arthritis
Nanoparticle
Targeting
Tumor

Access to Document

10.1007/978-981-10-4361-1_136

Cite this

@inproceedings{8d9e3578cce1420cb2dc12bdc4fd9c5f,

title = "Albumin-bound nanoparticles for targeted therapy",

abstract = "In this study, albumin nanoparticle formulations including a series of potential drugs for treating cancers, rheumatoid arthritis or pulmonary fibrosis, such as, paclitaxel, doxorubicin, TRAIL (TNF-related apoptosis inducing ligand) or tacrolimus, were developed by using nanoparticle albumin bound (Nab{\texttrademark}) technology. Marked targetability and in vivo efficacies of these albumin nanoparticles were demonstrated in mouse disease models.",

keywords = "Albumin, Albumin-bound technology, Arthritis, Nanoparticle, Targeting, Tumor",

author = "Youn, \{Yu Seok\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Singapore Pte Ltd. 2018.; 6th International Conference on the Development of Biomedical Engineering in Vietnam, BME 2016 ; Conference date: 27-06-2016 Through 29-06-2016",

year = "2018",

doi = "10.1007/978-981-10-4361-1\_136",

language = "English",

isbn = "9789811043604",

series = "IFMBE Proceedings",

publisher = "Springer Verlag",

pages = "801--803",

editor = "\{Vo Van\}, Toi and \{Nguyen Le\}, \{Thanh An\} and \{Nguyen Duc\}, Thang",

booktitle = "6th International Conference on the Development of Biomedical Engineering in Vietnam, BME6",

}

Youn, YS 2018, Albumin-bound nanoparticles for targeted therapy. in T Vo Van, TA Nguyen Le & T Nguyen Duc (eds), 6th International Conference on the Development of Biomedical Engineering in Vietnam, BME6. IFMBE Proceedings, vol. 63, Springer Verlag, pp. 801-803, 6th International Conference on the Development of Biomedical Engineering in Vietnam, BME 2016, Ho Chi Minh, Viet Nam, 27/06/16. https://doi.org/10.1007/978-981-10-4361-1_136

Albumin-bound nanoparticles for targeted therapy. / Youn, Yu Seok.
6th International Conference on the Development of Biomedical Engineering in Vietnam, BME6. ed. / Toi Vo Van; Thanh An Nguyen Le; Thang Nguyen Duc. Springer Verlag, 2018. p. 801-803 (IFMBE Proceedings; Vol. 63).

Research output: Chapter in Book/Report/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Albumin-bound nanoparticles for targeted therapy

AU - Youn, Yu Seok

N1 - Publisher Copyright: © Springer Nature Singapore Pte Ltd. 2018.

PY - 2018

Y1 - 2018

N2 - In this study, albumin nanoparticle formulations including a series of potential drugs for treating cancers, rheumatoid arthritis or pulmonary fibrosis, such as, paclitaxel, doxorubicin, TRAIL (TNF-related apoptosis inducing ligand) or tacrolimus, were developed by using nanoparticle albumin bound (Nab™) technology. Marked targetability and in vivo efficacies of these albumin nanoparticles were demonstrated in mouse disease models.

AB - In this study, albumin nanoparticle formulations including a series of potential drugs for treating cancers, rheumatoid arthritis or pulmonary fibrosis, such as, paclitaxel, doxorubicin, TRAIL (TNF-related apoptosis inducing ligand) or tacrolimus, were developed by using nanoparticle albumin bound (Nab™) technology. Marked targetability and in vivo efficacies of these albumin nanoparticles were demonstrated in mouse disease models.

KW - Albumin

KW - Albumin-bound technology

KW - Arthritis

KW - Nanoparticle

KW - Targeting

KW - Tumor

UR - https://www.scopus.com/pages/publications/85030830217

U2 - 10.1007/978-981-10-4361-1_136

DO - 10.1007/978-981-10-4361-1_136

M3 - Conference contribution

AN - SCOPUS:85030830217

SN - 9789811043604

T3 - IFMBE Proceedings

SP - 801

EP - 803

BT - 6th International Conference on the Development of Biomedical Engineering in Vietnam, BME6

A2 - Vo Van, Toi

A2 - Nguyen Le, Thanh An

A2 - Nguyen Duc, Thang

PB - Springer Verlag

T2 - 6th International Conference on the Development of Biomedical Engineering in Vietnam, BME 2016

Y2 - 27 June 2016 through 29 June 2016

ER -

Albumin-bound nanoparticles for targeted therapy

Abstract

Publication series

Conference

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this